Edison Investment Research - Goodwood Capital (GWC) H117 peak investment

Report

Edison Investment Research

Fiona Orford-Williams

H117 peak investment

Snakk Media (SNK), which connects brands to mobile audiences, has published its Q317 key operating milestones. These include a premium gross margin of 60%, compared to peers at 40%. This is a little below the company’s 62% FY17 target, with the year to date figure also now at 62%. The click-through rate softened slightly to 0.96% from 0.98% in Q217, still well above the mobile industry average (0.62%). Staff turnover at 12% was below the full year guidance of 24%, with the compensation to revenue ratio dropping back under the FY17 target. COO Joel Williams has now taken over the role of CEO, following Mark Ryan’s departure in December.

03/02/2017 4 EN

Underlying

Goodwood Capital

Snakk Media Limited. Snakk Media Limited is engaged in the provision of end-to-end mobile media solutions. The Company offers mobile phone enabled promotions and marketing services. The Company is in the business of developing and implementing mobile marketing campaigns that enable brands and advertising agencies to find and reach customers using applications, games and social media on smartphones, tablets and other mobile devices. The Company's smart products and technology platforms enable it to deliver smartphone, tablet and cross-screen advertising campaigns. It offers a range of media products to target audiences through data, including location, content and social signals. It offers various location solutions that enable mobile geo-location campaigns delivery. Its video offering includes video formats, such as Smart In-Banner Video and Zero Load High Definition (HD) Video. The Company offers TV Sync, which is a multi-screen product to match mobile campaigns with television commercials.

See profile

NZSNKE0001S9 NZX New Zealand

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Analysts

Fiona Orford-Williams

Other Reports on these Companies

Edison Investment Research

Snakk Media - Broadening out the offering

The benefits of the restructuring initiated in FY17 and continuing through FY18, should be more apparent in FY19 as the business runs for a full year on a lower underlying cost base. The upheaval in mobile advertising markets presents opportunities as well as threats and Snakk is diversifying its offering beyond geolocation in-app advertising to include a broader range of digital and data products. The group is placing shares at NZ$0.0425, raising $144k to ease its tight working capital position.

November 7, 2018 November 7, 2018 3 EN

Edison Investment Research

Snakk Media - Loss significantly reduced to near breakeven

The restructuring initiated in FY17 started to benefit the group in Q218 and Snakk Media finally returned to profit in its second half. Revenues for FY18 were close to the prior year at NZ$10.3m (NZ$10.6m), with increased self-service mobile advertising revenues offset by a decline in business in Southeast Asia (where overheads have been pared back). The cost base in FY19e will be lower with the full-year benefit. The group had year-end cash of NZ$1.1m, just below the current market capitalisation of NZ$1.3m.

June 8, 2018 June 8, 2018 4 EN

Edison Investment Research

Snakk Media - Improved cash performance

Snakk Media has issued its Q3 KOMs, which are broadly consistent with its full-year targets, with an outperformance of the compensation to revenue ratio and a higher staff turnover than indicated. This figure, though, is highly volatile due to the small numbers involved. The company is still undergoing a review of its capital strategy and the share price is unlikely to recover until the outcome of this is published.

February 5, 2018 February 5, 2018 4 EN

Dentsu Group - FY24 prospects weighted to H2

Dentsu’s Q1 results indicate a slow start to the year, with organic net revenue down by 3.7%. However, prospects are improving, buoyed by new business wins and weighted to H2, which leave full year expectations (and our forecasts) unchanged. The One dentsu initiative, bringing together skill sets in consulting, technology, media and creative, is supporting improved pitch win rates, and giving greater coherence and consistency to the group product and service offering. We expect this to be a central element of the new management medium-term strategy, set to be unveiled during H2. The rating rem...

1h / 29m 1h / 29m 1 EN

Pedro Fonseca

Pedro Fonseca

Record - AUME momentum and a sharper focus

Record’s Q424 trading update demonstrated continued growth in assets under management equivalent (AUME), which will support management fee growth into FY25. In FY24, AUME grew 17% to US$102.2bn, setting a new milestone in business scale. Net inflows for FY24 were US$6.8bn (FY23: US$9.1bn) or 8% of opening AUME. Performance fees of US$5.8m matched the record FY23 figure, and we expect this to offset the negative product mix in FY24. We have reduced our FY24e EPS by 1%, which is affected by £2.4bn in IT restructuring and impairment charges announced in March 2024. New CEO Dr Jan Witte is putting...

17h / 6m 17h / 6m 1 EN

Sean Conroy

Sean Conroy

Actinogen Medical - Funding in place through key catalysts

Actinogen announced a capital increase of up to A$8.9m on 3 May, consisting of a A$5.0m (gross) placement along with a shareholder rights offering (‘entitlement offer’) designed to raise up to A$3.9m (gross) from existing shareholders. The closing date of the rights offer is 29 May and, given that Actinogen shares are currently trading at c A$0.028, we assume full exercise of the rights offering in Q424 (Q2 CY24). The company expects that the proceeds (assuming full exercise of the rights offering) will extend its operating runway beyond the interim results release of the first 100 patients of...

May 15, 2024 May 15, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

H117 peak investment

Snakk Media - Broadening out the offering

Snakk Media - Loss significantly reduced to near breakeven

Snakk Media - Improved cash performance

Dentsu Group - FY24 prospects weighted to H2

Record - AUME momentum and a sharper focus

Actinogen Medical - Funding in place through key catalysts

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe